Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData’s pharmaceutical and healthcare report, “Stomach Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global gastric cancer market is expected to value $1,313m in 2016. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxotere’s generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the gastric cancer market. However, the new therapies are not expected go off-patent before 2016. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.

Scope

The scope of the report includes:

• Annualized global (gastrointestinal) stomach cancer market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are mTOR inhibitors, PARP inhibitors, microtubule inhibitors, VEGFR inhibitors, multiple tyrosine kinase inhibitors, Heat Shock Protein 90 inhibitors, Eg5 inhibitors, Farnesyl-OH-transferase inhibitors, angiogenesis inhibitors and combinations of several existing chemotherapies.
• Analysis of the current and future competition in the global stomach cancer market. The key market players covered include GlaxoSmithKline, Novartis Pharmaceuticals, Merck & Co, Eli Lilly and Company, Amgen, Fresenius Biotech GmBH, ACT Biotech, Genta Incorporated and Bristol Myers-Squibb.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future stomach cancer market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global gastrointestinal (stomach) cancer market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastrointestinal (stomach) cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global gastrointestinal (stomach) cancer market landscape? – Identify, understand and capitalize.

1 Table of Contents
    1.1 List of Tables
    1.2 List of Figures

2 Stomach Cancer: Market Characterization
    2.1 Overview
    2.2 Stomach Cancer Market Size
    2.3 Stomach Cancer Market Forecast and CAGR
    2.4 Drivers and Barriers for the Stomach Cancer Market
        2.4.1 Drivers for the Stomach Cancer Market
        2.4.2 Barriers for the Stomach Cancer Market
    2.5 Opportunity and Unmet Need
    2.6 Key Takeaway

3 Stomach Cancer Market: Competitive Assessment
    3.1 Overview
    3.2 Strategic Competitor Assessment
    3.3 Product Profiles of Major Marketed Drugs in the Stomach Cancer Market
        3.3.1 Herceptin (trastuzumab)
        3.3.2 Taxotere (docetaxel)
        3.3.3 Xeloda
        3.3.4 Gleevec (imatinib)
    3.4 Key Takeaway

4 Stomach Cancer Market: Pipeline Assessment
    4.1 Overview
    4.2 Strategic Pipeline Assessment
        4.2.1 Technology Trends Analytic Framework
    4.3 Stomach Cancer - Promising Drugs Under Clinical Development
    4.4 Molecule Profile for Promising Drugs Under Clinical Development
        4.4.1 Tykerb (Lapatinib)
        4.4.2 Afinitor (Everolimus)
        4.4.3 IMC-1121B (ramucirumab)
        4.4.4 Cetuximab plus capecitabine and cisplatin
    4.5 Stomach Cancer Market - Clinical Pipeline by Mechanism of Action
    4.6 Stomach Cancer Market - Pipeline by Clinical Phase of Development
        4.6.1 Stomach Cancer Market - Phase III Clinical Pipeline
        4.6.2 Stomach Cancer Market - Phase II Clinical Pipeline
        4.6.3 Stomach Cancer Market - Phase I Clinical Pipeline
    4.7 Discontinued/Suspended Drugs for Stomach Cancer
    4.8 Key Takeaway

5 Stomach Cancer: Implications for Future Market Competition

6 Stomach Cancer Market: Future Players in the Stomach Cancer Market
    6.1 Introduction
    6.2 GlaxoSmithKline
        6.2.1 Company Overview
        6.2.2 Business Description
    6.3 Novartis Pharmaceuticals
        6.3.1 Company Overview
        6.3.2 Business Description
    6.4 Eli Lilly and Company
        6.4.1 Company Overview
        6.4.2 Business Description
    6.5 Merck & Co
        6.5.1 Company Overview
        6.5.2 Business Description

7 Stomach Cancer Market: Appendix
    7.1 Definitions
    7.2 Acronyms
    7.3 Research Methodology
        7.3.1 Coverage
        7.3.2 Secondary Research
        7.3.3 Forecasting
        7.3.4 Primary Research
        7.3.5 Expert Panels
    7.4 Contact Us
    7.5 Disclaimer
    7.6 Sources

1.1 List of Tables
    Table 1: Stomach Cancer Market Historical Revenues ($m), 2001-2009
    Table 2: Stomach Cancer Market Forecasts ($m), 2009-2016
    Table 3: Major Marketed Products Comparison in Stomach Cancer Market, 2010
    Table 4: Stomach Cancer - Most Promising Drugs under Clinical Development, 2010
    Table 5: Stomach Cancer - Phase III Clinical Pipeline, 2010
    Table 6: Stomach Cancer - Phase II Clinical Pipeline, 2010
    Table 7: Stomach Cancer - Phase I Clinical Pipeline, 2010
    Table 8: List of Discontinued/Suspended Drugs for Stomach Cancer, 2010
    Table 9: GlaxoSmithKline - Clinical Pipeline for Stomach Cancer, 2010
    Table 10: Novartis Pharmaceuticals - Clinical Pipeline for Stomach Cancer, 2010
    Table 11: Eli Lilly and Company - Clinical Pipeline for Stomach Cancer, 2010
    Table 12: Merck & Co - Clinical Pipeline for Stomach Cancer, 2010

1.2 List of Figures
    Figure 1: Stomach Cancer Market Historical Revenues ($m), 2001-2009
    Figure 2: Stomach Cancer Market Forecasts ($m), 2009-2016
    Figure 3: Opportunity and Unmet Need in the Stomach Cancer Market, 2010
    Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Stomach Cancer Market, 2010
    Figure 5: Technology Trends Analytic Framework - Stomach Cancer Market, 2010
    Figure 6: Technology Trends Analytic Framework of the Stomach Cancer Pipeline - Description, 2010
    Figure 7: Stomach Cancer Market - Clinical Pipeline by Mechanism of Action, 2010
    Figure 8: Stomach Cancer Pipeline by Phase of Clinical Development, 2010
    Figure 9: Implications for Future Market Competition in Stomach Cancer, 2010
    Figure 10: Stomach Cancer Market - Clinical Pipeline by Company, 2010
    Figure 11: GlobalData Methodology, 2010